|

|

Area Editoriale


13/10/2023

The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review

DLD 2023

20/08/2023

Management of inflammatory bowel disease in the elderly: A review

DLD Digestive and Liver Disease 55 (2023) 1001–1009

18/07/2023

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

NEJM

04/06/2023

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

NEJM - E.V. Loftus, Jr., J. Panes, A.P. Lacerda, L. Peyrin‑Biroulet, G. D’Haens, R. Panaccione, W. Reinisch, E. Louis, M. Chen, H. Nakase, J. Begun, B.S. Boland, C. Phillips, M.-E.F. Mohamed, J. Liu, Z. Geng, T. Feng, E. Dubcenco, and J.-F. Colombel

31/05/2023

Use of biologics for the management of Crohn’s disease: IG-IBD technical review based on the GRADE methodology

Digestive and Liver Disease: June 2023 (Volume 55, Issue 6)

31/05/2023

Prevention of post-operative recurrence of Crohn’s disease among patients with prior anti-TNF αfailure: A retrospective multicenter study

Digestive and Liver Disease: June 2023 (Volume 55, Issue 6)

28/04/2023

Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis

Digestive and Liver Disease 55 (2023) 580–586

10/03/2023

Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial

OP08 at ECCO 18th - Jairath, V.; Feagan, B.G.; Danese, S.; Gionchetti, P.; Travis, S.

28/01/2023

Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn’s disease: Results from the ENEIDA registry

ENEIDA registry by GETECCU